The unanswered question: When to initiate antiretroviral therapy in children with HIV infection

Current Opinion in HIV and AIDS

Volumn 2, Issue 5, 2007, Pages 416-425

  Abrams, Elaine J ^a  

^a Columbia University ^*  (United States)

Author keywords

Antiretroviral therapy; CD4; Pediatrics; Treatment guidelines; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; ISONIAZID; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CLINICAL TRIAL; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; VIREMIA; VIRUS RESISTANCE;

EID: 34547922856     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282cef1ee     Document Type: Review

References (16)

1. Rutstein RM, Feingold A, Meislich D, et al. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997; 11:F107-F111.
2. Melvin AJ, Mohan KM, Arcuino LA, et al. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997; 16:968-974.
3. Yogev R. Balancing the upside and downside of antiretroviral therapy in children. JAMA 2005; 293:2273-2274.
4. Working group on Antiretroviral Therapy and Medical Management of HIV Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV Infection. 26 October 2006. http://aidinfo.nih.gov [Accessed 24 May 2007]
5. Sharland M, Blanche S, Castelli G, et al. The PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Medicine 2004; 5 (Suppl 2):61-86.
6. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access: recommendations for a public health approach; 2006. http://www.who.int/hiv/pub/ guidelines/art/en/index.html. [Accessed 24 May 2007]
7. UNAIDS. Report on the Global AIDS Epidemic 2006. Geneva: UNAIDS; 2006.
8. National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). National Heart, Lung and Blood Institute, National Institute of Health. NIH Publication No 02-5215, September 2002. http://www.nhlbi.nih.gov/guidelines/ cholesterol/index. [Accessed 24 May 2007]
9. US Department of Health and Human Services. The seventh report on the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute, National Institute of Health. NIH Publication No. 03-5223. December 2004. http://www.nhlbi.nih.gov/guidelines/hypertension/index.htm. [Accessed 24 May 2007]
10. Ofori-Mante J, Kaul A, Rigaud M, et al. Natural history of HIV infected pediatric long-term or slow progressor population after the first decade of life. Pediatr Infect Dis J 2007; 26:217-220. This is a description of the immunologic and virologic characteristics of 20 HIV-infected adolescents who received no ART prior to 10 years of age and maintained CD4 >25%.
11. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006; 118:e1745-e1757. The authors report on the relationship between a variety of health, demographic and psychosocial characteristics and self-reported adherence for 2088 children and their caregivers.
12. Mellins CA, Brackis-Cott E, Doleszal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23:1035-1041.
13. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004; 18:1753-1768.
14. Carter RJ, Weiner J, Abrams EJ, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41:453-460. In this study of 147 ART-experienced children with HIV, children receiving protease inhibitors were at significantly higher risk for hypercholesterolemia and hypertriglyceridemia.
15. Farley J, Gona P, Crain M, et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years) in PACTG 219C. J Acquir Immune Defic Syndr 2004; 38:480-487.
16. Ene L, Goetghebuer T, Hainaut M, et al. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007; 166:13-21. This study of 80 children aged 3-19 years reported fat redistribution in 27% of treated children, which was associated with longer duration of ART and stavudine or protease inhibitor use.